Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus CLARITIN D 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus CLARITIN D 24 HOUR.
CLARINEX-D 12 HOUR vs CLARITIN-D 24 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination